ICP-B381 / InnoCare - LARVOL DELTA

InnoCare Pharma…announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate clinical trials for ICP-B381, the novel bispecific ADC targeting PSMA and STEAP1, for the treatment of solid tumors including prostate cancer (GlobeNewswire) - "ICP-B381 is InnoCare’s first bispecific ADC to enter the clinic and the third ADC to enter clinical trials."

New trial • Prostate Cancer

ICP-B381: a differentiated PSMA/STEAP1 dual-targeting ADC with robust preclinical efficacy (InnoCare Pharma Press Release) - "In preclinical studies, ICP-B381 demonstrated robust and dose-dependent antitumor activity in a 22Rv1 human prostate cancer xenograft model, outperforming the corresponding single-target PSMA ADC and STEAP1 ADC at the same dose, with favorable tolerability. Its IND application has been submitted and accepted by CDE, and the U.S. IND application is expected to be submitted in September 2026."

IND • Preclinical • Prostate Cancer